Mifepristone

Major

Mifepristone Istradefylline Nourianz Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Ixazomib Ninlaro Increased CYP3A4 substrate exposure Details Mifepristone Lefamulin Xenleta Increased lefamulin exposure, an increased miFEPRIStone exposure, and an increased risk of QT interval prolongation Details Mifepristone Lenacapavir Injection Sunlenca Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Lenacapavir Oral Sunlenca Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Leniolisib Joenja Increased leniolisib exposure Details Mifepristone Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Mifepristone Letermovir Injection Prevymis Increased miFEPRIStone exposure Details Mifepristone Levofloxacin Levaquin Increased risk of QT interval prolongation Details Mifepristone Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Mifepristone Levonorgestrel After banger Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Levonorgestrel Intrauterine System Kyleena Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Linagliptin Tradjenta Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Loperamide Diamode An increased risk of QT interval prolongation, an increased risk of other ventricular arrhythmias, cardiac arrest, an increased lo... Details Mifepristone Loratadine Agistam® Increased CYP3A4 substrate exposure Details Mifepristone Lumateperone Caplyta Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Mifepristone Macitentan Opsumit Increased macitentan exposure Details Mifepristone Maraviroc Selzentry Increased maraviroc exposure Details Mifepristone Medroxyprogesterone Amen® Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Medroxyprogesterone Injection Depo-Provera Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Mefloquine Lariam® An increased risk of QT interval prolongation Details Mifepristone Methylergonovine Methergine Increased methylergonovine exposure and an increased risk of vasospasm, cerebral ischemia and/or ischemia of extremities Details Mifepristone Metronidazole Flagyl An increased risk of QT interval prolongation Details Mifepristone Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Mifepristone Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Mifepristone Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Mifepristone Midazolam Nasal Spray Nayzilam Increased CYP3A4 substrate exposure Details Mifepristone Midazolam Injection Nayzilam Increased CYP3A4 substrate exposure Details Mifepristone Mitapivat Aqvesme Increased CYP3A4 substrates exposure, reduced miFEPRIStone exposure and reduced efficacy of miFEPRIStone Details Mifepristone Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Mifepristone Moxifloxacin Avelox Increased risk of QT interval prolongation Details Mifepristone Moxifloxacin Injection Avelox Increased risk of QT interval prolongation Details Mifepristone Moxifloxacin Ophthalmic Moxeza® Increased risk of QT interval prolongation Details Mifepristone Nafcillin Injection Unipen® Injection Reduced miFEPRIStone exposure and reduced efficacy of miFEPRIStone Details Mifepristone Naldemedine Symproic Increased CYP3A4 substrate exposure Details Mifepristone Nateglinide Starlix® Increased CYP3A4 substrate exposure Details Mifepristone Nevirapine Viramune Increased CYP3A4 substrate exposure Details Mifepristone Nifedipine Adalat® Increased NIFEdipine exposure and an increased risk of hypotension, bradycardia, or acute renal injury Details Mifepristone Nintedanib Ofev Increased CYP3A4 substrate exposure Details